Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company dev

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen

JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicate

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option u

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the a

ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock    This prospectus relates to th

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and mainta

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the a

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing no

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the

https://www.dailymail.co.uk/health/article-14954333/dementia-jab-breakthrough-Alzheimers.html

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective anti

Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.48) per share which beat the a

UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers th

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 studySystemic exp

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea

Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after th

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased

U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 point

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly